Medifast (MED) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 12, 2013
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'MED	'
Entity Common Stock, Shares Outstanding	'	13,884,293
Entity Registrant Name	'MEDIFAST INC	'
Entity Central Index Key	'0000910329	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$47,980,000	$39,937,000
Accounts receivable-net of allowance for sales returns and doubtful accounts of $731,000 and $542,000	1,932,000	2,148,000
Inventory	17,451,000	20,804,000
Investment securities	34,028,000	20,057,000
Income taxes, prepaid	2,555,000	873,000
Prepaid expenses and other current assets	2,035,000	3,296,000
Deferred tax assets	875,000	1,460,000
Total current assets	106,856,000	88,575,000
Property, plant and equipment - net	41,135,000	40,109,000
Trademarks and intangibles - net	49,000	428,000
Other assets	356,000	1,139,000
TOTAL ASSETS	148,396,000	130,251,000
Current liabilities:	'	'
Accounts payable and accrued expenses	30,338,000	28,221,000
Current maturities of long-term debt and capital leases	220,000	528,000
Total current liabilities	30,558,000	28,749,000
Other liabilities:	'	'
Long-term debt, net of current portion	0	3,113,000
Capital leases, net of current portion	530,000	696,000
Deferred tax liabilities	5,970,000	6,907,000
Total liabilities	37,058,000	39,465,000
Stockholders' Equity:	'	'
Preferred stock, $.001 par value (1,500,000 authorized, no shares issued and outstanding)	0	0
Common stock; par value $.001 per share; 20,000,000 shares authorized; 15,542,118 and 15,525,955 issued; 13,884,293 and 13,767,380 issued and outstanding	16,000	16,000
Additional paid-in capital	42,285,000	40,191,000
Accumulated other comprehensive income	332,000	553,000
Retained earnings	95,213,000	76,534,000
Less: cost of 1,608,908 shares of common stock in treasury	-26,508,000	-26,508,000
Total stockholders' equity	111,338,000	90,786,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$148,396,000	$130,251,000

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accounts receivable, allowance for sales returns and doubtful accounts	$731,000	$542,000
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	1,500,000	1,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	20,000,000	20,000,000
Common stock, issued	15,542,118	15,525,955
Common stock, outstanding	13,884,293	13,767,380
Common stock in treasury, shares	1,608,908	1,608,908

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue	$86,480,000	$90,968,000	$279,595,000	$273,464,000
Cost of sales	21,627,000	22,632,000	69,403,000	68,233,000
Gross Profit	64,853,000	68,336,000	210,192,000	205,231,000
Selling, general, and administration	57,504,000	59,408,000	183,624,000	185,568,000
Income from operations	7,349,000	8,928,000	26,568,000	19,663,000
Other income	'	'	'	'
Interest and dividend income, net	167,000	64,000	317,000	226,000
Other income	362,000	-13,000	581,000	925,000
Nonoperating Income (Expense)	529,000	51,000	898,000	1,151,000
Income before income taxes	7,878,000	8,979,000	27,466,000	20,814,000
Provision for income taxes	2,205,000	1,771,000	8,787,000	6,803,000
Net income	$5,673,000	$7,208,000	$18,679,000	$14,011,000
Basic earnings per share	$0.41	$0.53	$1.35	$1.02
Diluted earnings per share	$0.41	$0.52	$1.34	$1.02
Weighted average shares outstanding -	'	'	'	'
Basic	13,884,293	13,705,188	13,852,155	13,709,702
Diluted	13,903,412	13,804,212	13,955,217	13,766,013

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net income	$5,673,000	$7,208,000	$18,679,000	$14,011,000
Other comprehensive income, net of tax	'	'	'	'
Change in fair value of marketable securities, net of tax	304,000	165,000	-4,000	292,000
Adjustment for net (gains)/losses realized and included in net income, net of tax	-32,000	-1,000	-217,000	-91,000
Total change in unrealized gains/losses on marketable securities, net of tax	272,000	164,000	-221,000	201,000
Other comprehensive income	272,000	164,000	-221,000	201,000
Comprehensive income	$5,945,000	$7,372,000	$18,458,000	$14,212,000

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid- In Capital	Retained Earnings	Accumulated other comprehensive income	Treasury Stock
Balance at Dec. 31, 2012	$90,786,000	$16,000	$40,191,000	$76,534,000	$553,000	($26,508,000)
Balance (in shares) at Dec. 31, 2012	'	15,525,955	'	'	'	'
Shares issued to executives (in shares)	'	16,163	'	'	'	'
Share-based compensation to executives and directors	1,772,000	'	1,772,000	'	'	'
Share-based compensation tax benefit	322,000	'	322,000	'	'	'
Net income	18,679,000	'	'	18,679,000	'	'
Net change in unrealized gain on investments	-221,000	'	'	'	-221,000	'
Balance at Sep. 30, 2013	$111,338,000	$16,000	$42,285,000	$95,213,000	$332,000	($26,508,000)
Balance (in shares) at Sep. 30, 2013	'	15,542,118	'	'	'	'

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net income	$18,679,000	$14,011,000
Adjustments to reconcile net income to net cash provided by operating activities from continuing operations:	'	'
Depreciation and amortization	7,912,000	8,219,000
Realized gain on investment securities, net	-337,000	-4,000
Share-based compensation	1,772,000	1,816,000
Deferred income taxes	-47,000	-440,000
Loss on disposal of fixed assets	85,000	59,000
Changes in assets and liabilities which provided (used) cash:	'	'
Accounts receivable	216,000	-1,255,000
Inventory	3,353,000	1,690,000
Prepaid expenses and other current assets	1,261,000	-19,000
Other assets	764,000	219,000
Accounts payable and accrued expenses	2,117,000	10,603,000
Income taxes	-1,682,000	4,828,000
Net cash provided by operating activities	34,093,000	39,727,000
Cash Flow from Investing Activities:	'	'
Sale of investment securities	7,416,000	7,140,000
Purchase of investment securities	-21,576,000	-6,802,000
Purchase of property and equipment	-8,644,000	-7,435,000
Net cash used in investing activities	-22,804,000	-7,097,000
Cash Flow from Financing Activities:	'	'
Repayment of long-term debt and capital leases	-3,587,000	-1,297,000
Decrease in note receivable	19,000	13,000
Excess tax benefits from share-based compensation	322,000	567,000
Purchase of treasury stock	0	-2,764,000
Net cash used in financing activities	-3,246,000	-3,481,000
NET CHANGE IN CASH AND CASH EQUIVALENTS	8,043,000	29,149,000
Cash and cash equivalents - beginning of the period	39,937,000	14,262,000
Cash and cash equivalents - end of period	47,980,000	43,411,000
Supplemental disclosure of cash flow information:	'	'
Interest paid	49,000	93,000
Income taxes paid	10,143,000	2,249,000
Supplemental disclosure of non cash activity:	'	'
Capitalized lease additions	$0	$104,000

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
Basis of Presentation	'
	1	Basis of Presentation
	The condensed unaudited interim consolidated financial statements included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. The condensed consolidated financial statements and notes are presented as permitted on Form 10-Q and do not contain information included in the Company’s annual statements and notes. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.
	The results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the year ending December 31, 2013 or any other portions thereof. Certain information in footnote disclosures normally included in annual financial statements has been condensed or omitted for the interim periods presented in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim consolidated financial statements.
	These financial statements do not contain all of the information and footnotes required by generally accepted accounting principles for complete financial statements. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included.
	The consolidated balance sheet as of December 31, 2012 is derived from the audited financial statements included in the Company’s Annual Report in Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2012 (the 2012 form 10-K), which should be read in conjunction with these consolidated financial statements.

Presentation_of_Financial_Stat

Presentation of Financial Statements	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
Presentation of Financial Statements	'
	2	Presentation of Financial Statements
	The Company’s condensed consolidated financial statements include the accounts of Medifast, Inc. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
	Certain amounts reported for prior periods have been reclassified to be consistent with the current period presentation. No reclassification in the consolidated financial statements had a material impact on the presentation.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2013
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
Recent Accounting Pronouncements	'
	3	Recent Accounting Pronouncements
	We have considered all new accounting pronouncements and have concluded that there are no new pronouncements that may have a material impact on our results of operations, financial condition, or cash flows, based on current information.

Revenue_Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2013
Revenue Recognition [Abstract]	'
Revenue Recognition	'
	4	Revenue Recognition
	Revenue is recognized net of discounts, rebates, promotional adjustments, price adjustments, and estimated returns and upon transfer of title and risk to the customer which primarily occurs at shipping (F.O.B. terms). Upon shipment, the Company has no further performance obligations and collection is reasonably assured as the majority of sales are paid for prior to shipping. Medifast Weight Control Centers’ program fees are recognized over the estimated service period.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	5	Inventories
	Inventories consist principally of packaged meal replacements held in the Company’s warehouses. Inventory is stated at the lower of cost or market, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventory for unsalable or obsolete inventory.
	Inventories consisted of the following at September 30, 2013 and December 31, 2012:
			2013		2012
	Raw Materials		$	5,235,000	$	5,685,000
	Packaging			730,000		653,000
	Non-food Finished Goods			796,000		961,000
	Finished Goods			10,936,000		13,857,000
	Reserve for Obsolete Inventory			-246,000		-352,000
			$	17,451,000	$	20,804,000

Intangible_Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	6	Intangible Assets
	The Company has acquired certain intangible assets, which include: customer lists, trademarks, patents and copyrights. The customer lists are being amortized over a 3-year period based on management’s best estimate of the expected useful life. The costs of trademarks, patents and copyrights are amortized over 2 to 7 years based on their estimated useful life.
			As of September 30, 2013				As of December 31, 2012
			Gross Carrying		Accumulated		Gross Carrying		Accumulated		Weighted-Avg.
			Amount		Amortization		Amount		Amortization		Amortization
											Period
	Customer lists		$	235,000	$	228,000	$	235,000	$	206,000	3 years
	Trademarks, patents, and copyrights			2,437,000		2,395,000		2,437,000		2,038,000	4 years
	Total		$	2,672,000	$	2,623,000	$	2,672,000	$	2,244,000
	Amortization expense for the three and nine months ended September 30, 2013 and 2012 was as follows:
			Three Months Ended September 30,				Nine Months Ended September  30,
			2013		2012		2013		2012
	Customer lists		$	7,000	$	20,000	$	22,000	$	60,000
	Trademarks, patents, and copyrights			111,000		132,000		357,000		351,000
	Total trademarks and intangibles		$	118,000	$	152,000	$	379,000	$	411,000
	Amortization expense is included in selling, general and administrative expenses.

Earnings_per_Share

Earnings per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	7	Earnings per Share
	Basic earnings per share (“EPS”) computations are calculated utilizing the weighted average number of common shares outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of common shares outstanding adjusted for the effect of dilutive common stock equivalents.
	The following table sets forth the computation of basic and diluted EPS for the three and nine months ended September 30:
			Three Months Ended September 30,				Nine Months Ended September 30,
			2013		2012		2013		2012
	Numerator:
	Net income		$	5,673,000	$	7,208,000	$	18,679,000	$	14,011,000
	Denominator:
	Weighted average shares of common stock outstanding			13,884,293		13,705,188		13,852,155		13,709,702
	Effect of dilutive common stock equivalents			19,119		99,024		103,062		56,311
	Weighted average diluted common shares outstanding			13,903,412		13,804,212		13,955,217		13,766,013
	EPS:
	Basic		$	0.41	$	0.53	$	1.35	$	1.02
	Diluted		$	0.41	$	0.52	$	1.34	$	1.02

Estimates

Estimates	9 Months Ended
	Sep. 30, 2013
Estimates [Abstract]	'
Estimates	'
	8	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods.   Actual results could differ from those estimates.

Financial_Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2013
Financial Instruments [Abstract]	'
Financial Instruments	'
	9	Financial Instruments
	Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:
	Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.
	Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
	Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value from the perspective of a market participant.
	The following table represents cash and the available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category recorded as cash and cash equivalents or investment securities as of September 30, 2013 and December 31, 2012:
			September 30, 2013
			Cost		Unrealized		Unrealized		Accrued		Estimated		Cash & Cash		Investment
					Gains		Losses		Interest		Fair Value		Equivalents		Securities
	Cash		$	45,816,000	$	-	$	-	$	-	$	45,816,000	$	45,816,000	$	-
	Level 1:
	Money Market Accounts			2,164,000		-		-		-		2,164,000		2,164,000		-
	Mutual Funds			9,426,000		52,000		-244,000		-		9,234,000		-		9,234,000
	Corporate Equity Securities			4,585,000		668,000		-98,000		-		5,155,000		-		5,155,000
	Government & Agency Securities			7,774,000		83,000		-76,000		31,000		7,812,000		-		7,812,000
				23,949,000		803,000		-418,000		31,000		24,365,000		2,164,000		22,201,000
	Level 2:
	Municipal Bonds			3,629,000		99,000		-		23,000		3,751,000		-		3,751,000
	Corporate Bonds			8,007,000		73,000		-57,000		53,000		8,076,000		-		8,076,000
				11,636,000		172,000		-57,000		76,000		11,827,000		-		11,827,000
	Total		$	81,401,000	$	975,000	$	-475,000	$	107,000	$	82,008,000	$	47,980,000	$	34,028,000
			December 31, 2012
			Cost		Unrealized		Unrealized		Accrued		Estimated		Cash & Cash		Investment
					Gains		Losses		Interest		Fair Value		Equivalents		Securities
	Cash		$	38,977,000	$	-	$	-	$	-	$	38,977,000	$	38,977,000	$	-
	Level 1:
	Money Market Accounts			960,000		-		-		-		960,000		960,000		-
	Mutual Funds			234,000		13,000		-1,000		-		246,000		-		246,000
	Corporate Equity Securities			1,853,000		489,000		-46,000		-		2,296,000		-		2,296,000
	Government & Agency Securities			7,004,000		180,000		-3,000		34,000		7,215,000		-		7,215,000
				10,051,000		682,000		-50,000		34,000		10,717,000		960,000		9,757,000
	Level 2:
	Municipal Bonds			4,197,000		124,000		-4,000		27,000		4,344,000		-		4,344,000
	Corporate Bonds			5,772,000		136,000		-2,000		50,000		5,956,000		-		5,956,000
				9,969,000		260,000		-6,000		77,000		10,300,000		-		10,300,000
	Total		$	58,997,000	$	942,000	$	-56,000	$	111,000	$	59,994,000	$	39,937,000	$	20,057,000

Sharebased_Compensation

Share-based Compensation	9 Months Ended
	Sep. 30, 2013
Share-Based Compensation [Abstract]	'
Share-based Compensation	'
	10	Shared-based Compensation
	The Company has issued restricted stock to employees and nonemployee directors generally with terms up to five years. The fair value is equal to the market price of the Company’s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period. The following table summarizes the restricted stock activity:
			Shares		Weighed-Average
					Grant Date Fair Value
	Unvested at December 31, 2012			149,667	$	8.21
	Granted			314,706		25.23
	Vested			-151,883		13.14
	Forfeited			-		-
	Unvested at September 30, 2013			312,490	$	22.95
	The total restricted stock awards vested and charged against income during the three months ended September 30, 2013 and 2012 was $620,000 and $360,000, respectively and $2.0 million and $1.8 million for the nine months ended September 30, 2013 and 2012, respectively. The total income tax benefit recognized in the consolidated statement of income for these restricted stock awards was approximately $211,000 and $139,000 for the three months ended September 30, 2013 and 2012, respectively and $602,000 and $702,000 for the nine months ended September 30, 2013 and 2012, respectively. The tax benefit recognized in additional paid-in capital upon vesting of restricted stock awards was approximately $224,000 and $104,000 for the three months ended September 30, 2013 and 2012, respectively and $322,000 and 567,000 for the nine months ended September 30, 2013 and 2012, respectively. There was approximately $7.2 million of total unrecognized compensation cost related to restricted stock awards as of September 30, 2013. The cost is expected to be recognized over a weighted-average period of approximately 4.4 years.

Business_Segments

Business Segments	9 Months Ended
	Sep. 30, 2013
Segment Reporting, Disclosure Of Entity's Reportable Segments [Abstract]	'
Business Segments	'
	11	Business Segments
	Operating segments are components of an enterprise about which separate financial information is available that is regularly reviewed by the chief operating decision maker about how to allocate resources and in assessing performance. The Company has two reportable operating segments: Medifast, and MWCC and Wholesale. The Medifast reporting segment consists of the following distribution channels: Medifast Direct and Take Shape For Life. The MWCC and Wholesale segment consists of Medifast Corporate and Franchise Weight Control Centers as well as Medifast Wholesale Physicians.
	Total assets and operating expense not identified with a specific segment are listed as “Other” and include items such as auditors’ fees, attorney’s fees, stock compensation expense and corporate governance related to NYSE, Sarbanes Oxley and SEC regulations. Evaluation of the performance of operating segments is based on their respective income from operations before taxes. The accounting policies of the segments are the same as those of the Company. The presentation and allocation of assets, liabilities and results of operations may not reflect the actual economic costs of the segments as stand-alone businesses. If a different basis of allocation were utilized, the relative contributions of the segments might differ, but management believes that the relative trends in segments would likely not be impacted.
	The following tables present segment information for the three and  nine months ended September 30, 2013 and 2012:
			Three Months Ended September, 2013
			Medifast		MWCC &		Other		Consolidated
					Wholesale
	Revenues		$	73,324,000	$	13,156,000	$	-	$	86,480,000
	Cost of Sales			18,120,000		3,507,000		-		21,627,000
	Selling, General and Administrative Expense			44,970,000		8,434,000		1,408,000		54,812,000
	Depreciation and Amortization			1,939,000		684,000		69,000		2,692,000
	Interest(net) and other			-306,000		3,000		-226,000		-529,000
	Income before income taxes		$	8,601,000	$	528,000	$	-1,251,000	$	7,878,000
	Segment Assets		$	91,370,000	$	12,450,000	$	44,576,000	$	148,396,000
			Three Months Ended September 30, 2012
			Medifast		MWCC &		Other		Consolidated
					Wholesale
	Revenues		$	76,777,000	$	14,191,000	$	-	$	90,968,000
	Cost of Sales			18,986,000		3,646,000		-		22,632,000
	Selling, General and Administrative Expense			46,118,000		9,311,000		1,012,000		56,441,000
	Depreciation and Amortization			2,068,000		841,000		58,000		2,967,000
	Interest(net) and other			30,000		5,000		-86,000		-51,000
	Income before income taxes		$	9,575,000	$	388,000	$	-984,000	$	8,979,000
	Segment Assets		$	82,402,000	$	17,362,000	$	28,536,000	$	128,300,000
			Nine Months Ended September, 2013
			Medifast		MWCC &		Other		Consolidated
					Wholesale
	Revenues		$	238,625,000	$	40,970,000	$	-	$	279,595,000
	Cost of Sales			58,790,000		10,613,000		-		69,403,000
	Selling, General and Administrative Expense			145,028,000		26,058,000		4,626,000		175,712,000
	Depreciation and Amortization			5,583,000		2,135,000		194,000		7,912,000
	Interest(net) and other			-228,000		7,000		-677,000		-898,000
	Income before income taxes		$	29,452,000	$	2,157,000	$	-4,143,000	$	27,466,000
	Segment Assets		$	91,370,000	$	12,450,000	$	44,576,000	$	148,396,000
			Nine Months Ended September 30, 2012
			Medifast		MWCC &		Other		Consolidated
					Wholesale
	Revenues		$	230,550,000	$	42,914,000	$	-	$	273,464,000
	Cost of Sales			57,694,000		10,539,000		-		68,233,000
	Selling, General and Administrative Expense			138,140,000		31,426,000		7,783,000		177,349,000
	Depreciation and Amortization			5,955,000		2,071,000		193,000		8,219,000
	Interest(net) and other			76,000		14,000		-1,241,000		-1,151,000
	Income before income taxes		$	28,685,000	$	-1,136,000	$	-6,735,000	$	20,814,000
	Segment Assets		$	82,402,000	$	17,362,000	$	28,536,000	$	128,300,000

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	12	Contingencies
	The Company filed a civil complaint on February 17, 2010 in the U.S. District Court (SD, Cal) against Barry Minkow and the Fraud Discovery Institute, Inc. (collectively, “Minkow”), iBusiness Reporting, and its editor William Lobdell, Tracy Coenen and Sequence, Inc. (collectively, “Coenen”), “Zee Yourself”, and Robert L. Fitzpatrick (“FitzPatrick”) for Defamation, Market Manipulation and Unfair Business Practices, alleging a scheme of market manipulation of Medifast stock for Defendants’ monetary gain, by damaging the business reputation of Medifast and its Take Shape For Life division. Bradley T. MacDonald, former Executive Chairman of Medifast and Company shareholder, joined the lawsuit individually.  The lawsuit seeks $270 million in compensatory damages, punitive damages, and ancillary relief.  In March 2011, the District Court granted in part and denied in part certain Anti-SLAPP Motions to Strike (i.e. motions to dismiss) previously filed by all Defendants.  The Company has appealed that portion of the District Court’s ruling which dismissed its defamation claims against Minkow and Coenen in the 9th Circuit Court of Appeals.  Defendant FitzPatrick’s motion was denied as to the Company’s defamation claim, and FitzPatrick has appealed that portion of the Court’s ruling.  Both appeals have been fully-briefed and oral argument was held on March 5, 2013.  On May 20, 2013, the Court deferred its decision on Medifast and FitzPatrick’s appeals pending the determination of a petition for rehearing en banc in another Anti-SLAPP appeal, Tarla Makaeff v. Trump University, LLC, Case No. 11-55016, filed on April 30, 2013.  That petition is currently pending before the Ninth Circuit.
	On July 20, 2012, Jason Pharmaceuticals, Inc., a wholly-owned subsidiary of the Company, signed a proposed consent decree with the Federal Trade Commission (“FTC”), in response to the FTC’s investigation of certain statements in the Company’s advertising for its weight-loss programs.  On September 17, 2012 the consent decree was entered and approved by the United States District Court for the District of Columbia. The consent decree replaces a previous consent order entered into by Jason Pharmaceuticals, Inc. and the FTC in 1992.  The FTC expressed concern that some of the Company’s advertising contained claims which were not compatible with current standards for substantiation.  Pursuant to the consent decree, the Company agreed to modify certain advertising claims in this regard and agreed to ensure that its clinical studies meet the protocol contained in the consent agreement.  The Company paid a civil penalty of $3.7 million to resolve the FTC’s concerns and avoid protracted legal proceedings.  The Company accrued for the penalty in the second quarter of 2012 as part of selling, general & administration expenses.

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories consisted of the following at September 30, 2013 and December 31, 2012:
		2013		2012
	Raw Materials	$	5,235,000	$	5,685,000
	Packaging		730,000		653,000
	Non-food Finished Goods		796,000		961,000
	Finished Goods		10,936,000		13,857,000
	Reserve for Obsolete Inventory		-246,000		-352,000
		$	17,451,000	$	20,804,000

Intangible_Assets_Tables

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	The Company has acquired certain intangible assets, which include: customer lists, trademarks, patents and copyrights. The customer lists are being amortized over a 3-year period based on management’s best estimate of the expected useful life. The costs of trademarks, patents and copyrights are amortized over 2 to 7 years based on their estimated useful life.
		As of September 30, 2013				As of December 31, 2012
		Gross Carrying		Accumulated		Gross Carrying		Accumulated		Weighted-Avg.
		Amount		Amortization		Amount		Amortization		Amortization
										Period
	Customer lists	$	235,000	$	228,000	$	235,000	$	206,000	3 years
	Trademarks, patents, and copyrights		2,437,000		2,395,000		2,437,000		2,038,000	4 years
	Total	$	2,672,000	$	2,623,000	$	2,672,000	$	2,244,000
Amortization expense	'
	Amortization expense for the three and nine months ended September 30, 2013 and 2012 was as follows:
		Three Months Ended September 30,				Nine Months Ended September  30,
		2013		2012		2013		2012
	Customer lists	$	7,000	$	20,000	$	22,000	$	60,000
	Trademarks, patents, and copyrights		111,000		132,000		357,000		351,000
	Total trademarks and intangibles	$	118,000	$	152,000	$	379,000	$	411,000

Earnings_per_Share_Tables

Earnings per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share, Basic and Diluted	'
	The following table sets forth the computation of basic and diluted EPS for the three and nine months ended September 30:
		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Numerator:
	Net income	$	5,673,000	$	7,208,000	$	18,679,000	$	14,011,000
	Denominator:
	Weighted average shares of common stock outstanding		13,884,293		13,705,188		13,852,155		13,709,702
	Effect of dilutive common stock equivalents		19,119		99,024		103,062		56,311
	Weighted average diluted common shares outstanding		13,903,412		13,804,212		13,955,217		13,766,013
	EPS:
	Basic	$	0.41	$	0.53	$	1.35	$	1.02
	Diluted	$	0.41	$	0.52	$	1.34	$	1.02

Financial_Instruments_Tables

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2013
Financial Instruments [Abstract]	'
Cash and Available For Sale Securities Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses and Fair Value By Significant Investment Category	'
	The following table represents cash and the available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category recorded as cash and cash equivalents or investment securities as of September 30, 2013 and December 31, 2012:
		September 30, 2013
		Cost		Unrealized		Unrealized		Accrued		Estimated		Cash & Cash		Investment
				Gains		Losses		Interest		Fair Value		Equivalents		Securities
	Cash	$	45,816,000	$	-	$	-	$	-	$	45,816,000	$	45,816,000	$	-
	Level 1:
	Money Market Accounts		2,164,000		-		-		-		2,164,000		2,164,000		-
	Mutual Funds		9,426,000		52,000		-244,000		-		9,234,000		-		9,234,000
	Corporate Equity Securities		4,585,000		668,000		-98,000		-		5,155,000		-		5,155,000
	Government & Agency Securities		7,774,000		83,000		-76,000		31,000		7,812,000		-		7,812,000
			23,949,000		803,000		-418,000		31,000		24,365,000		2,164,000		22,201,000
	Level 2:
	Municipal Bonds		3,629,000		99,000		-		23,000		3,751,000		-		3,751,000
	Corporate Bonds		8,007,000		73,000		-57,000		53,000		8,076,000		-		8,076,000
			11,636,000		172,000		-57,000		76,000		11,827,000		-		11,827,000
	Total	$	81,401,000	$	975,000	$	-475,000	$	107,000	$	82,008,000	$	47,980,000	$	34,028,000
		December 31, 2012
		Cost		Unrealized		Unrealized		Accrued		Estimated		Cash & Cash		Investment
				Gains		Losses		Interest		Fair Value		Equivalents		Securities
	Cash	$	38,977,000	$	-	$	-	$	-	$	38,977,000	$	38,977,000	$	-
	Level 1:
	Money Market Accounts		960,000		-		-		-		960,000		960,000		-
	Mutual Funds		234,000		13,000		-1,000		-		246,000		-		246,000
	Corporate Equity Securities		1,853,000		489,000		-46,000		-		2,296,000		-		2,296,000
	Government & Agency Securities		7,004,000		180,000		-3,000		34,000		7,215,000		-		7,215,000
			10,051,000		682,000		-50,000		34,000		10,717,000		960,000		9,757,000
	Level 2:
	Municipal Bonds		4,197,000		124,000		-4,000		27,000		4,344,000		-		4,344,000
	Corporate Bonds		5,772,000		136,000		-2,000		50,000		5,956,000		-		5,956,000
			9,969,000		260,000		-6,000		77,000		10,300,000		-		10,300,000
	Total	$	58,997,000	$	942,000	$	-56,000	$	111,000	$	59,994,000	$	39,937,000	$	20,057,000

Sharebased_Compensation_Tables

Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Share-Based Compensation [Abstract]	'
Restricted Stock Activity	'
	The Company has issued restricted stock to employees and nonemployee directors generally with terms up to five years. The fair value is equal to the market price of the Company’s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period. The following table summarizes the restricted stock activity:
		Shares		Weighed-Average
				Grant Date Fair Value
	Unvested at December 31, 2012		149,667	$	8.21
	Granted		314,706		25.23
	Vested		-151,883		13.14
	Forfeited		-		-
	Unvested at September 30, 2013		312,490	$	22.95

Business_Segments_Tables

Business Segments (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting, Disclosure Of Entity's Reportable Segments [Abstract]	'
Segment Information	'
	The following tables present segment information for the three and  nine months ended September 30, 2013 and 2012:
		Three Months Ended September, 2013
		Medifast		MWCC &		Other		Consolidated
				Wholesale
	Revenues	$	73,324,000	$	13,156,000	$	-	$	86,480,000
	Cost of Sales		18,120,000		3,507,000		-		21,627,000
	Selling, General and Administrative Expense		44,970,000		8,434,000		1,408,000		54,812,000
	Depreciation and Amortization		1,939,000		684,000		69,000		2,692,000
	Interest(net) and other		-306,000		3,000		-226,000		-529,000
	Income before income taxes	$	8,601,000	$	528,000	$	-1,251,000	$	7,878,000
	Segment Assets	$	91,370,000	$	12,450,000	$	44,576,000	$	148,396,000
		Three Months Ended September 30, 2012
		Medifast		MWCC &		Other		Consolidated
				Wholesale
	Revenues	$	76,777,000	$	14,191,000	$	-	$	90,968,000
	Cost of Sales		18,986,000		3,646,000		-		22,632,000
	Selling, General and Administrative Expense		46,118,000		9,311,000		1,012,000		56,441,000
	Depreciation and Amortization		2,068,000		841,000		58,000		2,967,000
	Interest(net) and other		30,000		5,000		-86,000		-51,000
	Income before income taxes	$	9,575,000	$	388,000	$	-984,000	$	8,979,000
	Segment Assets	$	82,402,000	$	17,362,000	$	28,536,000	$	128,300,000
		Nine Months Ended September, 2013
		Medifast		MWCC &		Other		Consolidated
				Wholesale
	Revenues	$	238,625,000	$	40,970,000	$	-	$	279,595,000
	Cost of Sales		58,790,000		10,613,000		-		69,403,000
	Selling, General and Administrative Expense		145,028,000		26,058,000		4,626,000		175,712,000
	Depreciation and Amortization		5,583,000		2,135,000		194,000		7,912,000
	Interest(net) and other		-228,000		7,000		-677,000		-898,000
	Income before income taxes	$	29,452,000	$	2,157,000	$	-4,143,000	$	27,466,000
	Segment Assets	$	91,370,000	$	12,450,000	$	44,576,000	$	148,396,000
		Nine Months Ended September 30, 2012
		Medifast		MWCC &		Other		Consolidated
				Wholesale
	Revenues	$	230,550,000	$	42,914,000	$	-	$	273,464,000
	Cost of Sales		57,694,000		10,539,000		-		68,233,000
	Selling, General and Administrative Expense		138,140,000		31,426,000		7,783,000		177,349,000
	Depreciation and Amortization		5,955,000		2,071,000		193,000		8,219,000
	Interest(net) and other		76,000		14,000		-1,241,000		-1,151,000
	Income before income taxes	$	28,685,000	$	-1,136,000	$	-6,735,000	$	20,814,000
	Segment Assets	$	82,402,000	$	17,362,000	$	28,536,000	$	128,300,000

Inventories_Detail

Inventories (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Schedule of Inventory [Line Items]	'	'
Raw Materials	$5,235,000	$5,685,000
Packaging	730,000	653,000
Non-food Finished Goods	796,000	961,000
Finished Goods	10,936,000	13,857,000
Reserve for Obsolete Inventory	-246,000	-352,000
Inventory	$17,451,000	$20,804,000

Intangible_Assets_customer_lis

Intangible Assets customer lists, trademarks, patents and copyrights (Detail) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$2,672,000	$2,672,000
Accumulated Amortization	2,623,000	2,244,000
Customer lists	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	235,000	235,000
Accumulated Amortization	228,000	206,000
Weighted-Avg. Amortization Period	'3 years	'
Trademarks, patents and copyrights	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	2,437,000	2,437,000
Accumulated Amortization	$2,395,000	$2,038,000
Weighted-Avg. Amortization Period	'4 years	'

Amortization_expense_Detail

Amortization expense (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Expected Amortization Expense [Line Items]	'	'	'	'
Amortization expense	$118,000	$152,000	$379,000	$411,000
Customer lists	'	'	'	'
Expected Amortization Expense [Line Items]	'	'	'	'
Amortization expense	7,000	20,000	22,000	60,000
Trademarks, patents and copyrights	'	'	'	'
Expected Amortization Expense [Line Items]	'	'	'	'
Amortization expense	$111,000	$132,000	$357,000	$351,000

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2013
Customer lists	'
Intangible Assests [Line Items]	'
Finite-Lived intangible asset, useful life	'3 years
Minimum | Trademarks, patents and copyrights	'
Intangible Assests [Line Items]	'
Finite-Lived intangible asset, useful life	'2 years
Maximum | Trademarks, patents and copyrights	'
Intangible Assests [Line Items]	'
Finite-Lived intangible asset, useful life	'7 years

Earnings_per_Share_Detail

Earnings per Share (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator:	'	'	'	'
Net income	$5,673,000	$7,208,000	$18,679,000	$14,011,000
Denominator:	'	'	'	'
Weighted average shares of common stock outstanding	13,884,293	13,705,188	13,852,155	13,709,702
Effect of dilutive common stock equivalents	$19,119	$99,024	$103,062	$56,311
Weighted average diluted common shares outstanding	13,903,412	13,804,212	13,955,217	13,766,013
EPS:	'	'	'	'
Basic	$0.41	$0.53	$1.35	$1.02
Diluted	$0.41	$0.52	$1.34	$1.02

AvailableForSale_Securities_Ad

Available-For-Sale Securities Adjusted cost (Detail) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Cash and Cash Equivalents and Marketable Securites [Line Items]	'	'	'	'
Cost	$81,401,000	$58,997,000	'	'
Unrealized Gains	975,000	942,000	'	'
Unrealized Losses	-475,000	-56,000	'	'
Accrued Interest	107,000	111,000	'	'
Estimated Fair Value	82,008,000	59,994,000	'	'
Cash & Cash Equivalents	47,980,000	39,937,000	43,411,000	14,262,000
Investment Securities	34,028,000	20,057,000	'	'
Cash	'	'	'	'
Cash and Cash Equivalents and Marketable Securites [Line Items]	'	'	'	'
Cost	45,816,000	38,977,000	'	'
Unrealized Gains	0	0	'	'
Unrealized Losses	0	0	'	'
Accrued Interest	0	0	'	'
Estimated Fair Value	45,816,000	38,977,000	'	'
Cash & Cash Equivalents	45,816,000	38,977,000	'	'
Investment Securities	0	0	'	'
Fair Value, Inputs, Level 1	'	'	'	'
Cash and Cash Equivalents and Marketable Securites [Line Items]	'	'	'	'
Cost	23,949,000	10,051,000	'	'
Unrealized Gains	803,000	682,000	'	'
Unrealized Losses	-418,000	-50,000	'	'
Accrued Interest	31,000	34,000	'	'
Estimated Fair Value	24,365,000	10,717,000	'	'
Cash & Cash Equivalents	2,164,000	960,000	'	'
Investment Securities	22,201,000	9,757,000	'	'
Fair Value, Inputs, Level 1 | Money Market Accounts	'	'	'	'
Cash and Cash Equivalents and Marketable Securites [Line Items]	'	'	'	'
Cost	2,164,000	960,000	'	'
Unrealized Gains	0	0	'	'
Unrealized Losses	0	0	'	'
Accrued Interest	0	0	'	'
Estimated Fair Value	2,164,000	960,000	'	'
Cash & Cash Equivalents	2,164,000	960,000	'	'
Investment Securities	0	0	'	'
Fair Value, Inputs, Level 1 | Mutual Funds	'	'	'	'
Cash and Cash Equivalents and Marketable Securites [Line Items]	'	'	'	'
Cost	9,426,000	234,000	'	'
Unrealized Gains	52,000	13,000	'	'
Unrealized Losses	-244,000	-1,000	'	'
Accrued Interest	0	0	'	'
Estimated Fair Value	9,234,000	246,000	'	'
Cash & Cash Equivalents	0	0	'	'
Investment Securities	9,234,000	246,000	'	'
Fair Value, Inputs, Level 1 | Corporate Equity Securities	'	'	'	'
Cash and Cash Equivalents and Marketable Securites [Line Items]	'	'	'	'
Cost	4,585,000	1,853,000	'	'
Unrealized Gains	668,000	489,000	'	'
Unrealized Losses	-98,000	-46,000	'	'
Accrued Interest	0	0	'	'
Estimated Fair Value	5,155,000	2,296,000	'	'
Cash & Cash Equivalents	0	0	'	'
Investment Securities	5,155,000	2,296,000	'	'
Fair Value, Inputs, Level 1 | Government Agency Securities	'	'	'	'
Cash and Cash Equivalents and Marketable Securites [Line Items]	'	'	'	'
Cost	7,774,000	7,004,000	'	'
Unrealized Gains	83,000	180,000	'	'
Unrealized Losses	-76,000	-3,000	'	'
Accrued Interest	31,000	34,000	'	'
Estimated Fair Value	7,812,000	7,215,000	'	'
Cash & Cash Equivalents	0	0	'	'
Investment Securities	7,812,000	7,215,000	'	'
Fair Value, Inputs, Level 2	'	'	'	'
Cash and Cash Equivalents and Marketable Securites [Line Items]	'	'	'	'
Cost	11,636,000	9,969,000	'	'
Unrealized Gains	172,000	260,000	'	'
Unrealized Losses	-57,000	-6,000	'	'
Accrued Interest	76,000	77,000	'	'
Estimated Fair Value	11,827,000	10,300,000	'	'
Cash & Cash Equivalents	0	0	'	'
Investment Securities	11,827,000	10,300,000	'	'
Fair Value, Inputs, Level 2 | Municipal Bonds	'	'	'	'
Cash and Cash Equivalents and Marketable Securites [Line Items]	'	'	'	'
Cost	3,629,000	4,197,000	'	'
Unrealized Gains	99,000	124,000	'	'
Unrealized Losses	0	-4,000	'	'
Accrued Interest	23,000	27,000	'	'
Estimated Fair Value	3,751,000	4,344,000	'	'
Cash & Cash Equivalents	0	0	'	'
Investment Securities	3,751,000	4,344,000	'	'
Fair Value, Inputs, Level 2 | Corporate Bond Securities	'	'	'	'
Cash and Cash Equivalents and Marketable Securites [Line Items]	'	'	'	'
Cost	8,007,000	5,772,000	'	'
Unrealized Gains	73,000	136,000	'	'
Unrealized Losses	-57,000	-2,000	'	'
Accrued Interest	53,000	50,000	'	'
Estimated Fair Value	8,076,000	5,956,000	'	'
Cash & Cash Equivalents	0	0	'	'
Investment Securities	$8,076,000	$5,956,000	'	'

Summary_of_Restricted_Stock_Ac

Summary of Restricted Stock Activity (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Shares	'
Unvested at December 31, 2012	149,667
Granted	314,706
Vested	-151,883
Forfeited	0
Unvested at September 30, 2013	312,490
Weighted-Average Grant Date Fair Value	'
Unvested at December 31, 2012	$8.21
Granted	$25.23
Vested	$13.14
Forfeited	$0
Unvested at September 30, 2013	$22.95

Sharebased_Compensation_Additi

Share-based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Tax benefit recognized in additional paid-in capital upon vesting of restricted stock awards	$224,000	$104,000	$322,000	$567,000
Restricted Stock	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Restricted stock awards vested and charged	620,000	360,000	2,000,000	1,800,000
Total income tax benefit recognized related to restricted stock awards	211,000	139,000	602,000	702,000
Unrecognized compensation cost related to restricted stock awards	$7,200,000	'	$7,200,000	'
Compensation cost recognition weighted average period	'	'	'4 years 4 months 24 days	'

Segment_information_Detail

Segment information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues	$86,480,000	$90,968,000	$279,595,000	$273,464,000	'
Cost of Sales	21,627,000	22,632,000	69,403,000	68,233,000	'
Selling, General and Administrative Expense	54,812,000	56,441,000	175,712,000	177,349,000	'
Depreciation and Amortization	2,692,000	2,967,000	7,912,000	8,219,000	'
Interest(net) and other	-529,000	-51,000	-898,000	-1,151,000	'
Income before income taxes	7,878,000	8,979,000	27,466,000	20,814,000	'
Segment Assets	148,396,000	128,300,000	148,396,000	128,300,000	130,251,000
Medifast Inc	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues	73,324,000	76,777,000	238,625,000	230,550,000	'
Cost of Sales	18,120,000	18,986,000	58,790,000	57,694,000	'
Selling, General and Administrative Expense	44,970,000	46,118,000	145,028,000	138,140,000	'
Depreciation and Amortization	1,939,000	2,068,000	5,583,000	5,955,000	'
Interest(net) and other	-306,000	30,000	-228,000	76,000	'
Income before income taxes	8,601,000	9,575,000	29,452,000	28,685,000	'
Segment Assets	91,370,000	82,402,000	91,370,000	82,402,000	'
Mwcc and Wholesale	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues	13,156,000	14,191,000	40,970,000	42,914,000	'
Cost of Sales	3,507,000	3,646,000	10,613,000	10,539,000	'
Selling, General and Administrative Expense	8,434,000	9,311,000	26,058,000	31,426,000	'
Depreciation and Amortization	684,000	841,000	2,135,000	2,071,000	'
Interest(net) and other	3,000	5,000	7,000	14,000	'
Income before income taxes	528,000	388,000	2,157,000	-1,136,000	'
Segment Assets	12,450,000	17,362,000	12,450,000	17,362,000	'
Other	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues	0	0	0	0	'
Cost of Sales	0	0	0	0	'
Selling, General and Administrative Expense	1,408,000	1,012,000	4,626,000	7,783,000	'
Depreciation and Amortization	69,000	58,000	194,000	193,000	'
Interest(net) and other	-226,000	-86,000	-677,000	-1,241,000	'
Income before income taxes	-1,251,000	-984,000	-4,143,000	-6,735,000	'
Segment Assets	$44,576,000	$28,536,000	$44,576,000	$28,536,000	'

Contingencies_Additional_Infor

Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 17, 2012	Sep. 30, 2013
Operating and Capital Leases [Line Items]	'	'
Loss Contingency, Damages Sought, Value	'	$270
Payments to civil penalty	$3.70	'